The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV : Assessment of alternative dosing regimens
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.13244 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Baralee Punyawudho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Rifampin, Oxazines, HIV Infections, Drug Interactions. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Systems Research Institute, National Research Council of Thailand.
Abstract (Originalsprache)
Tuberculosis is the most common opportunistic infection in individuals with HIV, and rifampicin is crucial in the treatment of tuberculosis. Drug–drug interactions complicate the use of DTG in HIV/TB co‐infection, which makes drug administration more difficult. This study aimed to develop the population pharmacokinetic model of DTG when co‐administered with rifampicin. The developed model was further used to investigate different dosing regimens. Forty HIV/TB‐co‐infected participants receiving DTG 50 mg once daily (OD) with food or DTG 50 mg twice daily (b.i.d.) without food were included in the analysis. Intensive pharmacokinetic samples were collected. The data were analyzed using a nonlinear mixed‐effects modeling approach. A total of 332 DTG concentrations from 40 PLWH were analyzed. The pharmacokinetics of DTG co‐administered with rifampicin can be best described by a one‐compartment model with first‐order absorption (incorporating lag time) and elimination. Total bilirubin was the only covariate that significantly affected CL/F. DTG 50 mg b.i.d. results in the highest proportion of individuals achieving in vitro IC 90 of 0.064 mg/L and in vivo EC 90 of 0.3 mg/L, while more than 90% of individuals receiving DTG 100 mg OD would achieve the in vitro IC 90 target. Therefore, DTG 100 mg OD could serve as an alternative regimen by minimizing the difficulty of drug administration. However, its clinical efficacy requires additional evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
- HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
- Division of Infectious disease, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Department of Medicine, Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Korea.
ORCID-Profile: Baralee Punyawudho, Thornthun Ueaphongsukkit, Sivaporn Gatechompol, Sasiwimol Ubolyam, Yong Soon Cho, Jae Gook Shin, Anchalee Avihingsanon
Förderung
- Health Systems Research Institute
- National Research Council of Thailand
Zitieren
APA
Punyawudho, B., Chanruang, A., Ueaphongsukkit, T., Gatechompol, S., Ubolyam, S., Cho, Y. S., Shin, J. G., & Avihingsanon, A. (2025). The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV : Assessment of alternative dosing regimens. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13244
Vancouver
Punyawudho B, Chanruang A, Ueaphongsukkit T, Gatechompol S, Ubolyam S, Cho YS, et al. The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV : Assessment of alternative dosing regimens. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13244
BibTeX
@article{Punyawudho2025,
author = {Punyawudho, Baralee and Chanruang, Anan and Ueaphongsukkit, Thornthun and Gatechompol, Sivaporn and Ubolyam, Sasiwimol and Cho, Yong Soon and Shin, Jae Gook and Avihingsanon, Anchalee},
title = {The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV : Assessment of alternative dosing regimens},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.13244}
}
EUVIMED